⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEVA News
Teva Pharmaceutical Industries Limited American Depositary Shares
As Enterprises Move AI Agents Into Production, OpenBox AI and Temporal Introduce Runtime Governance for Long-Running Agents
prnewswire.com
NFLX
SNOW
CHKP
DDOG
CRM
S
AMZN
GOOG
MSFT
IBM
ORCL
CSCO
INTC
NVDA
AMD
META
ADBE
PYPL
CMCSA
VZ
T
BA
GE
CAT
DIS
MCD
KO
PEP
JNJ
PG
XOM
CVX
WMT
HD
UNH
MA
V
JPM
BAC
WFC
C
GS
MS
AXP
BLK
PRU
MET
AIG
CB
MSCI
SPGI
ICE
NDAQ
AMAT
MU
ASML
KLAC
ADSK
CDNS
MRVL
QCOM
TXN
LRCX
ADI
MCHP
NXPI
ON
ALGN
BIIB
GILD
AMGN
REGN
VRTX
BMY
PFE
MRK
ABBV
LLY
JAZZ
AZN
SNY
NVS
TEVA
ACN
TMO
ISRG
DASH
UBER
LYFT
GOOGL
AAPL
TSLA
GM
F
RIVN
LCID
NIO
XPEV
PLTR
SMCI
CRWD
PANW
SNPS
MDT
EW
ABT
CI
HUM
CNC
ETSY
BKNG
EXPE
MAR
HLT
IHG
WYNN
LVS
MGM
CCL
RCL
NCLH
AAL
UAL
DAL
LUV
ALK
JBLU
$Z, $ZG Stock Drop: Zillow Stock Plummets 17% after Anticompetitive Agreement Revealed - Securities Fraud Class Action is Ongoing
accessnewswire.com
Z
ZG
TSLA
TEVA
AeroVironment (NASDAQ:AVAV) SCAR Contract Cancellation Triggers Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit
globenewswire.com
AVAV
TSLA
TEVA
Teva und Polpharma Biologics geben globale Lizenzvereinbarung für einen Biosimilar-Kandidaten zu Ocrevus® (Ocrelizumab) zur Behandlung von Multipler Sklerose bekannt
businesswire.com
TEVA
Riassunto: Teva e Polpharma Biologics annunciano un accordo di licenza globale relativo a un candidato biosimilare per Ocrevus® (ocrelizumab) nella sclerosi multipla
businesswire.com
TEVA
Resumen: Teva y Polpharma Biologics anuncian un acuerdo de licencia internacional para un candidato a biosimilar de Ocrevus® (ocrelizumab) para la esclerosis múltiple
businesswire.com
TEVA
Samenvatting: Teva en Polpharma Biologics kondigen een globale licentieovereenkomst aan voor een biosimilair kandidaatgeneesmiddel voor Ocrevus® (ocrelizumab) ter behandeling van multiple sclerose
businesswire.com
TEVA
Teva et Polpharma Biologics annoncent la signature d’un accord de licence mondial portant sur un candidat biosimilaire à l’Ocrevus® (ocrelizumab) destiné au traitement de la sclérose en plaques
businesswire.com
TEVA
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis
businesswire.com
TEVA
EMBC Alert: Embecta Securities Class Action After Stock Dropped 57% is Pending - August 17 Legal Deadline is Imminent
accessnewswire.com
EMBC
TSLA
TEVA